<DOC>
	<DOCNO>NCT00675051</DOCNO>
	<brief_summary>Pulmonary hypertension progressive life threaten condition . It characterize severe remodel pulmonary vessel wall , obstructive plexiform lesion , multi-focal thrombosis , enhance vasoconstriction . All characteristic contribute increase pulmonary vascular resistance . Circulating endothelial microparticles ( EMPs ) play integral role pathogenesis perpetuation pulmonary hypertension . Levels EMPs consider reliable biological parameter endothelial injury . We propose assess evolution circulate pulmonary venous EMPs patient PH . Assessments make initiation Endothelin-1 ( ET-1 ) Receptor blocker therapy , correlate pattern change mean PAP , 6 Minutes Walking Distance test , circulate Endothelin-1 value . Measurements endothelial microparticle circulating level ( assess flow cytometry method ) make , 1 month 3 month initiation therapy .</brief_summary>
	<brief_title>Effect Endothelin-1 Receptor Blockade Circulating Endothelial Microparticles Levels Patients With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patient 's + 18 year suspect precapillary pulmonary hypertension Prescribed Endothelial 1 receptor blocker Currently take endotheliumactive vasodilator therapy . Hemoglobin / hematocrit level blood lower normal limit . Left ventricle dysfunction ( LVEF &lt; 50 % ) LV enddiastolic pressure &gt; 15 mmHg ) Recent history ( &lt; 3 month ) pulmonary embolism Liver failure abnormal liver function test ; aortic mitral regurgitation stenosis Current medication endothelin1 receptor antagonist , prostacyclin analogue type 5 phosphodiesterase inhibitor . Subjects condition know associated increase circulate endothelial microparticle numers , chronic renal failure ( Creatinine Clearance &lt; 50 ml/min/m2 ) acute coronary syndrome uncontrolled system hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>To determine trans-pulmonary gradient level EMPs patient PH</keyword>
	<keyword>To determine EMPs measure pulmonary capillary wedge position correlate even strongly severity PH circulating level</keyword>
	<keyword>To determine PH therapy ET-1 receptor blocker modify EMPs level</keyword>
</DOC>